Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Company expects strong organic growth in sales, EBITDA in 2022
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Subscribe To Our Newsletter & Stay Updated
